Gene info: ID 150

Gene: ADRA2A

GENE ID: 150

Synonyms: ADRA2|ADRA2R|ADRAR|ALPHA2AAR|ZNF32

Description: adrenoceptor alpha 2A

Gene type: protein-coding

Location: 10q25.2

dbXrefs: Ensembl:ENSG00000150594 MIM:104210 Vega:OTTHUMG00000019050 UniprotKB:P08913

RefSeq: NG_012020.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD|OD|ND|AD

# Publications: 8

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 8.385e-1 (AD) 9.204e-2 (ND)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg05329352	chr10:112838983	ADRA2A		2.200e-22	Smoking	27651444
cg05329352	chr10:112838983	ADRA2A		3.670e-11	Smoking	28686328

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
SLC8A3	0.827
XKR7	0.826
ARL4D	0.814
GALNT14	0.808
RASSF5	0.792
ABCC12	0.789
MRAP2	0.786
STX1A	0.786
NUAK1	0.785
KCNF1	0.782

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PARD3B	-0.542
STON2	-0.522
CYP11A1	-0.509
C10orf105	-0.501
PARD3	-0.496
RHOD	-0.484
ASB4	-0.483
HVCN1	-0.477
ACSM5	-0.471
CDC14A	-0.471

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00246	Ziprasidone	Small Molecule	146939-27-7	Approved	Target
DB00248	Cabergoline	Small Molecule	81409-90-7	Approved	Target
DB00268	Ropinirole	Small Molecule	91374-21-9	Approved\|Investigational	Target
DB00320	Dihydroergotamine	Small Molecule	511-12-6	Approved\|Investigational	Target
DB00321	Amitriptyline	Small Molecule	50-48-6	Approved	Target
DB00334	Olanzapine	Small Molecule	132539-06-1	Approved\|Investigational	Target
DB00363	Clozapine	Small Molecule	5786-21-0	Approved	Target
DB00368	Norepinephrine	Small Molecule	51-41-2	Approved	Target
DB00370	Mirtazapine	Small Molecule	85650-52-8	Approved	Target
DB00408	Loxapine	Small Molecule	1977-10-2	Approved	Target
DB00413	Pramipexole	Small Molecule	104632-26-0	Approved\|Investigational	Target
DB00449	Dipivefrin	Small Molecule	52365-63-6	Approved	Target
DB00457	Prazosin	Small Molecule	19216-56-9	Approved	Target
DB00484	Brimonidine	Small Molecule	59803-98-4	Approved	Target
DB00543	Amoxapine	Small Molecule	14028-44-5	Approved	Target
DB00555	Lamotrigine	Small Molecule	84057-84-1	Approved\|Investigational	Target
DB00575	Clonidine	Small Molecule	4205-90-7	Approved	Target
DB00589	Lisuride	Small Molecule	18016-80-3	Approved\|Investigational	Target
DB00629	Guanabenz	Small Molecule	5051-62-7	Approved\|Investigational	Target
DB00633	Dexmedetomidine	Small Molecule	113775-47-6	Approved	Target
DB00656	Trazodone	Small Molecule	19794-93-5	Approved\|Investigational	Target
DB00668	Epinephrine	Small Molecule	51-43-4	Approved	Target
DB00692	Phentolamine	Small Molecule	50-60-2	Approved	Target
DB00696	Ergotamine	Small Molecule	113-15-5	Approved	Target
DB00697	Tizanidine	Small Molecule	51322-75-9	Approved\|Investigational	Target
DB00714	Apomorphine	Small Molecule	58-00-4	Approved\|Investigational	Target
DB00726	Trimipramine	Small Molecule	739-71-9	Approved	Target
DB00734	Risperidone	Small Molecule	106266-06-2	Approved\|Investigational	Target
DB00751	Epinastine	Small Molecule	80012-43-7	Approved\|Investigational	Target
DB00797	Tolazoline	Small Molecule	59-98-3	Approved	Target
DB00800	Fenoldopam	Small Molecule	67227-56-9	Approved	Target
DB00852	Pseudoephedrine	Small Molecule	90-82-4	Approved	Target
DB00865	Benzphetamine	Small Molecule	156-08-1	Approved\|Illicit	Target
DB00925	Phenoxybenzamine	Small Molecule	59-96-1	Approved	Target
DB00935	Oxymetazoline	Small Molecule	1491-59-4	Approved\|Investigational	Target
DB00964	Apraclonidine	Small Molecule	66711-21-5	Approved	Target
DB00968	Methyldopa	Small Molecule	555-30-6	Approved	Target
DB01018	Guanfacine	Small Molecule	29110-47-2	Approved\|Investigational	Target
DB01136	Carvedilol	Small Molecule	72956-09-3	Approved\|Investigational	Target
DB01142	Doxepin	Small Molecule	1668-19-5	Approved\|Investigational	Target
DB01149	Nefazodone	Small Molecule	83366-66-9	Approved\|Withdrawn	Target
DB01186	Pergolide	Small Molecule	66104-22-1	Approved\|Investigational\|Withdrawn	Target
DB01200	Bromocriptine	Small Molecule	25614-03-3	Approved\|Investigational	Target
DB01224	Quetiapine	Small Molecule	111974-69-7	Approved	Target
DB01238	Aripiprazole	Small Molecule	129722-12-9	Approved\|Investigational	Target
DB01267	Paliperidone	Small Molecule	144598-75-4	Approved	Target
DB01363	Ephedra	Small Molecule	-	Approved\|Nutraceutical\|Withdrawn	Target
DB01392	Yohimbine	Small Molecule	146-48-5	Approved\|Investigational	Target
DB01403	Methotrimeprazine	Small Molecule	60-99-1	Approved\|Investigational	Target
DB01472	4-Methoxyamphetamine	Small Molecule	64-13-1	Experimental\|Illicit	Target
DB01577	Methamphetamine	Small Molecule	537-46-2	Approved\|Illicit	Target
DB01608	Propericiazine	Small Molecule	2622-26-6	Approved\|Investigational	Target
DB01624	Zuclopenthixol	Small Molecule	53772-83-1	Approved\|Investigational	Target
DB04855	Dronedarone	Small Molecule	141626-36-0	Approved	Target
DB04948	Lofexidine	Small Molecule	31036-80-3	Approved\|Investigational	Target
DB05492	Epicept NP-1	Small Molecule	-	Investigational	Target
DB06148	Mianserin	Small Molecule	24219-97-4	Approved\|Investigational	Target
DB06216	Asenapine	Small Molecule	65576-45-6	Approved	Target
DB06229	Ocaperidone	Small Molecule	129029-23-8	Investigational	Target
DB06262	Droxidopa	Small Molecule	23651-95-8	Approved\|Investigational	Target
DB06623	Flupirtine	Small Molecule	56995-20-1	Approved\|Investigational	Target
DB06694	Xylometazoline	Small Molecule	526-36-3	Approved\|Investigational	Target
DB06711	Naphazoline	Small Molecule	835-31-4	Approved	Target
DB08815	Lurasidone	Small Molecule	367514-87-2	Approved\|Investigational	Target
DB09242	Moxonidine	Small Molecule	75438-57-2	Approved\|Investigational	Target
DB09244	Pirlindole	Small Molecule	60762-57-4	Approved	Target
DB09286	Pipamperone	Small Molecule	1893-33-0	Approved\|Investigational	Target
DB11124	Racepinephrine	Small Molecule	329-65-7	Approved	Target
DB11738	Rilmenidine	Small Molecule	54187-04-1	Approved\|Investigational	Target
DB00217	Bethanidine	Small Molecule	55-73-2	Approved	Target
DB00397	Phenylpropanolamine	Small Molecule	14838-15-4	Approved\|Withdrawn	Target
DB00477	Chlorpromazine	Small Molecule	50-53-3	Approved\|Investigational	Target
DB00540	Nortriptyline	Small Molecule	72-69-5	Approved	Target
DB00543	Amoxapine	Small Molecule	14028-44-5	Approved	Target
DB00841	Dobutamine	Small Molecule	34368-04-2	Approved	Target
DB00934	Maprotiline	Small Molecule	10262-69-8	Approved\|Investigational	Target
DB01049	Ergoloid mesylate	Small Molecule	8067-24-1	Approved	Target
DB01151	Desipramine	Small Molecule	50-47-5	Approved\|Investigational	Target
DB06678	Esmirtazapine	Small Molecule	61337-87-9	Investigational	Target
DB06707	Levonordefrin	Small Molecule	829-74-3	Approved	Target
DB09167	Dosulepin	Small Molecule	113-53-1	Approved	Target
DB09194	Etoperidone	Small Molecule	52942-31-1	Withdrawn	Target
DB09195	Lorpiprazole	Small Molecule	108785-69-9	Approved	Target
DB09202	Cirazoline	Small Molecule	59939-16-1	Experimental	Target
DB09304	Setiptiline	Small Molecule	57262-94-9	Approved	Target
DB13025	Tiapride	Small Molecule	51012-32-9	Approved\|Investigational	Target
DB00182	Amphetamine	Small Molecule	300-62-9	Approved\|Illicit\|Investigational	Target
DB01365	Mephentermine	Small Molecule	100-92-5	Approved	Target
DB09205	Moxisylyte	Small Molecule	54-32-0	Approved\|Investigational	Target
DB09229	Aranidipine	Small Molecule	86780-90-7	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C060229	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	"1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]"	10742289
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether analog results in decreased expression of ADRA2A mRNA"	19095052
C010654	(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane	"(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane binds to and results in decreased activity of ADRA2A protein"	8397342
C010654	(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane	"(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane binds to and results in decreased activity of ADRA2A protein"	8397342
C038890	2,3,4,7,8-pentachlorodibenzofuran	"2,3,4,7,8-pentachlorodibenzofuran results in decreased expression of ADRA2A mRNA"	21724226
C014211	2,3,7,8-tetrachlorodibenzofuran	"2,3,7,8-tetrachlorodibenzofuran results in decreased expression of ADRA2A mRNA"	21724226
C058525	2-methoxyidazoxan	ADRA2A protein binds to 2-methoxyidazoxan	20030735
C058525	2-methoxyidazoxan	Epinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	Norepinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	Oxymetazoline inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
C058525	2-methoxyidazoxan	xylometazoline inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
C056298	5,6-dihydroxy-1-(2-imidazolinyl)tetralin	"5,6-dihydroxy-1-(2-imidazolinyl)tetralin binds to and results in increased activity of ADRA2A protein"	10742289
C098657	5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine	"5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine results in decreased activity of ADRA2A protein"	16595736\|1793401
C098657	5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine	"[5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine results in decreased activity of ADRA2A protein] which results in decreased susceptibility to Clonidine"	16595736\|1793401
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of ADRA2A mRNA	22230336
D000082	Acetaminophen	Acetaminophen affects the expression of ADRA2A mRNA	17562736
D020106	Acrylamide	Acrylamide results in decreased expression of ADRA2A mRNA	28959563
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of ADRA2A mRNA	19770486
D000638	Amiodarone	Amiodarone results in increased expression of ADRA2A mRNA	19774075
C014983	amitraz	amitraz results in decreased activity of ADRA2A protein	21251949
C014983	amitraz	amitraz binds to and results in increased activity of ADRA2A protein	10582558
C014983	amitraz	[Idazoxan binds to and results in decreased activity of ADRA2A protein] which results in decreased susceptibility to amitraz	10582558
D000661	Amphetamine	Amphetamine binds to and results in increased activity of ADRA2A protein	14999075
C006632	arsenic trioxide	arsenic trioxide results in decreased expression of ADRA2A mRNA	26705709
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite affects the expression of ADRA2A mRNA"	17331233
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in decreased expression of ADRA2A mRNA"	19446018
D001262	Atenolol	ADRA2A gene SNP affects the susceptibility to Atenolol	15614026
C050701	atipamezole	atipamezole binds to and results in decreased activity of ADRA2A protein	15220790
D001280	Atrazine	Atrazine results in decreased expression of ADRA2A mRNA	25929836
D001280	Atrazine	Atrazine results in increased expression of ADRA2A mRNA	22378314
D001280	Atrazine	Atrazine affects the activity of ADRA2A protein	11071396
D001280	Atrazine	Atrazine binds to ADRA2A protein	11071396
D001564	Benzo(a)pyrene	Benzo(a)pyrene promotes the reaction [AHR protein binds to ADRA2A promoter]	19654925
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of ADRA2A mRNA	19770486
D004958	Estradiol	Estradiol results in increased expression of ADRA2A mRNA	15713686
C495703	bis(2-chloroethoxy)methane	bis(2-chloroethoxy)methane affects the expression of ADRA2A mRNA	16844662
C006780	bisphenol A	bisphenol A results in decreased expression of ADRA2A mRNA	25181051
C000611646	bisphenol F	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADRA2A mRNA	28628672
D000068438	Brimonidine Tartrate	Brimonidine Tartrate inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D000068438	Brimonidine Tartrate	Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]	10742289
D000068438	Brimonidine Tartrate	Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]	10742289
D000068438	Brimonidine Tartrate	Prazosin inhibits the reaction [Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]]	10742289
D000068438	Brimonidine Tartrate	Yohimbine inhibits the reaction [Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]]	10742289
D000068438	Brimonidine Tartrate	Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein	12598592
D000068438	Brimonidine Tartrate	Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein	8397342
D000068438	Brimonidine Tartrate	Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein	12208771\|8397342
C072126	BRL 41992	BRL 41992 binds to and results in decreased activity of ADRA2A protein	8397342
C072126	BRL 41992	BRL 41992 binds to and results in decreased activity of ADRA2A protein	8397342
C072125	BRL 44408	BRL 44408 binds to and results in decreased activity of ADRA2A protein	8397342
C072125	BRL 44408	BRL 44408 binds to and results in decreased activity of ADRA2A protein	8397342
C072125	BRL 44408	[BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]]	11312645
C072125	BRL 44408	[BRL 44408 binds to and results in decreased activity of ADRA2A protein] which results in decreased susceptibility to oxcarbazepine	17959985
C072125	BRL 44408	BRL 44408 binds to and results in decreased activity of ADRA2A protein	11312645\|1526563
D015124	8-Bromo Cyclic Adenosine Monophosphate	8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA	22079614
D002118	Calcium	[Epinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium	20030735
D002118	Calcium	[Norepinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium	20030735
D002211	Capsaicin	ADRA2A results in decreased susceptibility to Capsaicin	15220790
D002220	Carbamazepine	Carbamazepine affects the expression of ADRA2A mRNA	25979313
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of ADRA2A mRNA	16644059
D004390	Chlorpyrifos	Chlorpyrifos affects the expression of ADRA2A mRNA	17452286
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of ADRA2A mRNA	18812211
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADRA2A gene	20938992
D003000	Clonidine	ADRA2A protein results in increased susceptibility to Clonidine	16814767
D003000	Clonidine	Clonidine binds to and results in increased activity of ADRA2A protein	16814767
D003000	Clonidine	Clonidine binds to and results in increased activity of ADRA2A protein	10217548
D003000	Clonidine	Clonidine binds to and results in increased activity of ADRA2A protein	12560108\|1259859
D003000	Clonidine	"[5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine results in decreased activity of ADRA2A protein] which results in decreased susceptibility to Clonidine"	16595736\|1793401
D003000	Clonidine	Clonidine binds to and results in increased activity of ADRA2A protein	14656453\|2811564
D003375	Coumestrol	[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA	18310284
D003375	Coumestrol	ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]	18310284
D003471	Cuprizone	Cuprizone results in increased expression of ADRA2A mRNA	26577399
C007168	cyanazine	cyanazine affects the activity of ADRA2A protein	11071396
C007168	cyanazine	cyanazine binds to ADRA2A protein	11071396
D016572	Cyclosporine	Cyclosporine results in decreased methylation of ADRA2A promoter	27989131
C014347	decitabine	decitabine affects the expression of ADRA2A mRNA	17145863
C014347	decitabine	decitabine results in increased expression of ADRA2A mRNA	19194470
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADRA2A mRNA	28628672
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADRA2A mRNA	28628672
D020927	Dexmedetomidine	Dexmedetomidine binds to and results in increased activity of ADRA2A protein	15627480
D020927	Dexmedetomidine	Dexmedetomidine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D020927	Dexmedetomidine	Dexmedetomidine binds to and results in increased activity of ADRA2A protein	15220790
D003976	Diazinon	Diazinon results in increased expression of ADRA2A mRNA	17452286
D004280	Dobutamine	Dobutamine binds to and results in increased activity of ADRA2A protein	16024912
D004298	Dopamine	Dopamine binds to ADRA2A protein	10336518
D017292	Doxazosin	Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D017292	Doxazosin	Doxazosin results in decreased expression of ADRA2A protein	10694191
D017292	Doxazosin	Doxazosin results in increased activity of ADRA2A protein	10694191
C118739	entinostat	entinostat results in increased expression of ADRA2A mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
D004837	Epinephrine	ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]	17680988
D004837	Epinephrine	ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]	17680988
D004837	Epinephrine	ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]	17680988
D004837	Epinephrine	ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]	17680988
D004837	Epinephrine	Epinephrine binds to and results in increased activity of ADRA2A protein	20030735
D004837	Epinephrine	[Epinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium	20030735
D004837	Epinephrine	Epinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
D004837	Epinephrine	Epinephrine results in increased activity of ADRA2A protein	17341653
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADRA2A gene	20938992
C069837	fullerene C60	fullerene C60 results in decreased expression of ADRA2A mRNA	19167457
C004312	glycidol	glycidol results in decreased expression of ADRA2A mRNA	24915197
D016316	Guanfacine	Guanfacine binds to and results in increased activity of ADRA2A protein	14999075\|1855270
C000625835	HFPO2 compound	HFPO2 compound results in increased expression of ADRA2A mRNA	27553808
C000625836	HFPO4 compound	HFPO4 compound results in increased expression of ADRA2A mRNA	27553808
D019329	Idazoxan	[Idazoxan binds to and results in decreased activity of ADRA2A protein] which results in decreased susceptibility to amitraz	10582558
D019329	Idazoxan	Idazoxan binds to and results in decreased activity of ADRA2A protein	10582558
C044484	Imiloxan	Imiloxan binds to and results in decreased activity of ADRA2A protein	8397342
C044484	Imiloxan	Imiloxan binds to and results in decreased activity of ADRA2A protein	8397342
D007190	Indapamide	Indapamide results in increased expression of ADRA2A protein	2829625
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADRA2A mRNA	28628672
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADRA2A mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADRA2A mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADRA2A mRNA	28628672
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of ADRA2A mRNA	26752646
D007854	Lead	Lead affects the expression of ADRA2A mRNA	28903495
D000069056	Lurasidone Hydrochloride	Lurasidone Hydrochloride binds to ADRA2A protein	20404009
D020926	Medetomidine	ADRA2A protein affects the susceptibility to Medetomidine	20083574
D020926	Medetomidine	Medetomidine binds to and results in increased activity of ADRA2A protein	12598592
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADRA2A gene	20938992
D008748	Methylcholanthrene	Methylcholanthrene promotes the reaction [AHR protein binds to ADRA2A promoter]	20348232
D008748	Methylcholanthrene	[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of ADRA2A mRNA	23519560
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of ADRA2A mRNA	26011545
C043482	moxonidine	moxonidine binds to and results in increased activity of ADRA2A protein	10217548
D037742	Nanotubes, Carbon	"Nanotubes, Carbon affects the expression of ADRA2A mRNA"	23845593\|2555468
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of ADRA2A mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of ADRA2A mRNA"	27106021
D009532	Nickel	Nickel results in increased expression of ADRA2A mRNA	18812211
C028007	nickel monoxide	nickel monoxide results in decreased expression of ADRA2A mRNA	19167457
D008771	Nordefrin	Nordefrin binds to and results in increased activity of ADRA2A protein	16595736
D009638	Norepinephrine	"1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]"	10742289
D009638	Norepinephrine	Brimonidine Tartrate inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D009638	Norepinephrine	Dexmedetomidine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D009638	Norepinephrine	Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D009638	Norepinephrine	Norepinephrine binds to and results in increased activity of ADRA2A protein	10742289\|2003073
D009638	Norepinephrine	[Norepinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium	20030735
D009638	Norepinephrine	Norepinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
D009638	Norepinephrine	Prazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D009638	Norepinephrine	talipexole inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D009638	Norepinephrine	Thapsigargin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D009638	Norepinephrine	Yohimbine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D009638	Norepinephrine	ADRA2A protein affects the abundance of Norepinephrine	20083574
D009638	Norepinephrine	[ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine	20083574
D009638	Norepinephrine	Norepinephrine binds to ADRA2A protein	10336518
D009638	Norepinephrine	ADRA2A protein affects the secretion of Norepinephrine	11312645
D009638	Norepinephrine	[BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]]	11312645
C106996	NRA 0045	NRA 0045 binds to ADRA2A protein	9223539
C036006	oxcarbazepine	[BRL 44408 binds to and results in decreased activity of ADRA2A protein] which results in decreased susceptibility to oxcarbazepine	17959985
D010109	Oxymetazoline	Oxymetazoline binds to ADRA2A protein	20030735
D010109	Oxymetazoline	Oxymetazoline inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
C086401	pentabromodiphenyl ether	pentabromodiphenyl ether analog results in decreased expression of ADRA2A mRNA	19095052
C029261	phenethylamine	phenethylamine binds to ADRA2A protein	20217639
D010634	Phenobarbital	Phenobarbital affects the expression of ADRA2A mRNA	19136022
D010646	Phentolamine	Phentolamine binds to and results in decreased activity of ADRA2A protein	8397342
D010646	Phentolamine	Phentolamine binds to and results in decreased activity of ADRA2A protein	8397342
D010656	Phenylephrine	Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]	10742289
D010656	Phenylephrine	Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]	10742289
D010656	Phenylephrine	Prazosin inhibits the reaction [Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]]	10742289
D010656	Phenylephrine	Yohimbine inhibits the reaction [Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]]	10742289
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA"	27188386
D010665	Phenylpropanolamine	Phenylpropanolamine binds to ADRA2A protein	20217639
D010852	Picrotoxin	Picrotoxin results in increased expression of ADRA2A mRNA	15170462
C006253	pirinixic acid	NCF1 protein affects the reaction [pirinixic acid results in decreased expression of ADRA2A mRNA]	17950772
C006253	pirinixic acid	pirinixic acid affects the expression of ADRA2A mRNA	19136022
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of ADRA2A mRNA	19710929
C006253	pirinixic acid	[pirinixic acid co-treated with PPARA] results in increased expression of ADRA2A mRNA	20813756
C006253	pirinixic acid	pirinixic acid results in decreased expression of ADRA2A mRNA	17950772
C006253	pirinixic acid	pirinixic acid results in increased expression of ADRA2A mRNA	18301758\|2081375
C006253	pirinixic acid	PPARA protein promotes the reaction [pirinixic acid results in decreased expression of ADRA2A mRNA]	17950772
D011188	Potassium	[BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]]	11312645
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of ADRA2A mRNA	23608068
D011224	Prazosin	Prazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D011224	Prazosin	Prazosin inhibits the reaction [Phenylephrine promotes the reaction [Brimonidine Tartrate binds to and results in increased activity of ADRA2A protein]]	10742289
D011224	Prazosin	Prazosin binds to and results in decreased activity of ADRA2A protein	8397342
D011224	Prazosin	Prazosin binds to and results in decreased activity of ADRA2A protein	8397342
D000069583	Pregabalin	Pregabalin results in decreased expression of ADRA2A mRNA	22489711
D011374	Progesterone	Progesterone results in increased expression of ADRA2A mRNA	15713686
C400294	radolmidine	radolmidine binds to and results in increased activity of ADRA2A protein	15220790
D012110	Reserpine	Reserpine results in increased expression of ADRA2A mRNA	11264240
D015474	Isotretinoin	Isotretinoin results in increased expression of ADRA2A mRNA	20436886
C032302	rilmenidine	rilmenidine binds to ADRA2A protein	10217548
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of ADRA2A mRNA	25895662
C054935	SK&F 104078	SK&F 104078 binds to and results in decreased activity of ADRA2A protein	8397342
C054935	SK&F 104078	SK&F 104078 binds to and results in decreased activity of ADRA2A protein	8397342
D013578	Synephrine	Synephrine binds to ADRA2A protein	20217639
C024763	talipexole	talipexole inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D013629	Tamoxifen	Tamoxifen results in increased expression of ADRA2A mRNA	25123088
D013739	Testosterone	Testosterone results in increased expression of ADRA2A mRNA	15713686
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ADRA2A mRNA	26377647
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of ADRA2A mRNA	21724226
D013755	Tetradecanoylphorbol Acetate	[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of ADRA2A mRNA	23519560
D019284	Thapsigargin	Thapsigargin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
C009495	titanium dioxide	titanium dioxide results in decreased expression of ADRA2A mRNA	23557971
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased methylation of ADRA2A gene	26756918
C052342	topiramate	topiramate results in increased expression of ADRA2A mRNA	22489711
D014212	Tretinoin	Tretinoin results in increased expression of ADRA2A mRNA	21934132
C012589	trichostatin A	trichostatin A results in increased expression of ADRA2A mRNA	24935251
D014635	Valproic Acid	Valproic Acid affects the expression of ADRA2A mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of ADRA2A mRNA	24383497\|2493525
D014635	Valproic Acid	Valproic Acid results in increased methylation of ADRA2A gene	29154799
D014991	Xylazine	[BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]]	11312645
C009695	xylometazoline	xylometazoline binds to ADRA2A protein	20030735
C009695	xylometazoline	xylometazoline inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]	20030735
D015016	Yohimbine	Yohimbine inhibits the reaction [Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]]	10742289
D015016	Yohimbine	Yohimbine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]	10742289
D015016	Yohimbine	Yohimbine binds to and results in decreased activity of ADRA2A protein	17666864
D015016	Yohimbine	Yohimbine binds to and results in decreased activity of ADRA2A protein	8397342
D015016	Yohimbine	Yohimbine binds to and results in decreased activity of ADRA2A protein	8397342
D015016	Yohimbine	Yohimbine binds to and results in decreased activity of ADRA2A protein	14656453\|7753402

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004935	adrenergic receptor activity	-	IBA	21873635
GO:0004938	alpha2-adrenergic receptor activity	-	IDA	10948191
GO:0004938	alpha2-adrenergic receptor activity	-	ISS	1354394
GO:0005515	protein binding	-	IPI	16531006
GO:0019901	protein kinase binding	-	IPI	15653687
GO:0031692	alpha-1B adrenergic receptor binding	-	ISS	-
GO:0031696	alpha-2C adrenergic receptor binding	-	IPI	16605244
GO:0031996	thioesterase binding	-	IPI	19477270
GO:0032795	heterotrimeric G-protein binding	-	IDA	10948191
GO:0042803	protein homodimerization activity	-	IDA	16605244
GO:0046982	protein heterodimerization activity	-	IPI	16605244
GO:0046982	protein heterodimerization activity	-	ISS	-
GO:0051379	epinephrine binding	-	IDA	2823383 10948191
GO:0051380	norepinephrine binding	-	IDA	2823383

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001819	positive regulation of cytokine production	-	IDA	17655843
GO:0006940	regulation of smooth muscle contraction	-	IEA	-
GO:0007165	signal transduction	-	TAS	2823383 10896916
GO:0007186	G-protein coupled receptor signaling pathway	-	ISS	19965390
GO:0007186	G-protein coupled receptor signaling pathway	-	TAS	-
GO:0007188	adenylate cyclase-modulating G-protein coupled receptor signaling pathway	-	IBA	21873635
GO:0007189	adenylate cyclase-activating G-protein coupled receptor signaling pathway	-	ISS	12529373
GO:0007193	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway	-	ISS	1354394
GO:0007265	Ras protein signal transduction	-	TAS	8226727
GO:0007266	Rho protein signal transduction	-	TAS	9624180
GO:0007267	cell-cell signaling	-	IBA	21873635
GO:0008284	positive regulation of cell proliferation	-	TAS	10896916
GO:0010700	negative regulation of norepinephrine secretion	-	NAS	16531006
GO:0010700	negative regulation of norepinephrine secretion	-	TAS	19477270
GO:0019229	regulation of vasoconstriction	-	IEA	-
GO:0030036	actin cytoskeleton organization	-	TAS	9624180
GO:0030168	platelet activation	-	IEA	-
GO:0030335	positive regulation of cell migration	-	IMP	17655843
GO:0032147	activation of protein kinase activity	-	IDA	15653687
GO:0032148	activation of protein kinase B activity	-	IDA	17215105
GO:0032811	negative regulation of epinephrine secretion	-	NAS	16531006
GO:0032870	cellular response to hormone stimulus	-	IGI	10948198
GO:0035625	epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway	-	IDA	17215105 17655843
GO:0042593	glucose homeostasis	-	IMP	10952463
GO:0043268	positive regulation of potassium ion transport	-	ISS	1354394
GO:0043406	positive regulation of MAP kinase activity	-	IDA	19477270
GO:0043410	positive regulation of MAPK cascade	-	IDA	10948191
GO:0045741	positive regulation of epidermal growth factor-activated receptor activity	-	IDA	17655843
GO:0045955	negative regulation of calcium ion-dependent exocytosis	-	IC	10952463
GO:0046676	negative regulation of insulin secretion	-	IMP	10952463
GO:0050796	regulation of insulin secretion	-	TAS	-
GO:0050892	intestinal absorption	-	TAS	17655843
GO:0050995	negative regulation of lipid catabolic process	-	IGI	10948198
GO:0051044	positive regulation of membrane protein ectodomain proteolysis	-	IDA	17655843
GO:0051926	negative regulation of calcium ion transport	-	ISS	-
GO:0061179	negative regulation of insulin secretion involved in cellular response to glucose stimulus	-	IMP	19965390
GO:0071875	adrenergic receptor signaling pathway	-	IDA	10948191
GO:0071880	adenylate cyclase-activating adrenergic receptor signaling pathway	-	IBA	21873635
GO:0071880	adenylate cyclase-activating adrenergic receptor signaling pathway	-	ISS	-
GO:0071881	adenylate cyclase-inhibiting adrenergic receptor signaling pathway	-	IDA	10948191
GO:0071882	phospholipase C-activating adrenergic receptor signaling pathway	-	IDA	10948191
GO:0090303	positive regulation of wound healing	-	IMP	17655843
GO:1901020	negative regulation of calcium ion transmembrane transporter activity	-	ISS	1354394

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	IDA	19477270
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IBA	21873635
GO:0005887	integral component of plasma membrane	-	IDA	2823383 10948191 10948198
GO:0016323	basolateral plasma membrane	-	TAS	17655843
GO:0043235	receptor complex	-	IDA	10948191

KEGG ID	KEGG Term
hsa04080	Neuroactive ligand-receptor interaction

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-1430728	Metabolism	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-163685	Integration of energy metabolism	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	TAS
R-HSA-375280	Amine ligand-binding receptors	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-390696	Adrenoceptors	TAS
R-HSA-392023	Adrenaline signalling through Alpha-2 adrenergic receptor	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-400042	Adrenaline,noradrenaline inhibits insulin secretion	TAS
R-HSA-418594	G alpha (i) signalling events	TAS
R-HSA-418597	G alpha (z) signalling events	TAS
R-HSA-422356	Regulation of insulin secretion	TAS
R-HSA-500792	GPCR ligand binding	TAS
R-HSA-5683826	Surfactant metabolism	TAS
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-76009	Platelet Aggregation (Plug Formation)	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
16636200	Do allelic variants in alpha2A and alpha2C adrenergic receptors predispose to hypertension in blacks? (2006 Jun)	Li JL	Hypertension
18842695	ADRA2A polymorphism and smoking in a Turkish population. (2008 Apr)	Karahalil B	Toxicol Ind Health
21070505	Multiple polymorphisms in genes of the adrenergic stress system confer vulnerability to alcohol abuse. (2012 Jan)	Clarke TK	Addict Biol
29333880	Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. (2018)	Crist RC	Am J Drug Alcohol Abuse
26549422	alpha2A -Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users. (2017 Mar)	Havranek MM	Addict Biol
23177301	[Genetic polymorphisms as tool indicators for individual vulnerability to smoking behaviour]. (2013 Jan 19)	Barrot C	Med Clin (Barc)
19562039	Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. (2009 Jun 29)	Sober S	PLoS One
28300812	[A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine]. (2016)	Kibitov capital A, Cyrilliccapital O, Cyrillic	Zh Nevrol Psikhiatr Im S S Korsakova